In the US, XGEVA (denosumab systemic) is a member of the drug class miscellaneous bone resorption inhibitors and is used to treat Giant Cell Tumor of Bone, Hypercalcemia of Malignancy, Osteolytic Bone Lesions of Multiple Myeloma and Osteolytic Bone Metastases of Solid Tumors.
Ingredient matches for XGEVA
Denosumab is reported as an ingredient of XGEVA in the following countries:
- Bosnia & Herzegowina
- Croatia (Hrvatska)
- Hong Kong
- United Kingdom
- United States
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.